Browsing Tag
apremilast
4 posts
Zasocitinib meets all endpoints in Phase 3 trials, Takeda (NYSE: TAK) eyes FDA submission in 2026
Takeda’s once-daily TYK2 pill hits PASI 100 in Phase 3 psoriasis trials. Find out what this means for rivals, regulators, and Takeda’s pipeline strategy.
Bristol-Myers Squibb wraps up $74bn acquisition of Celgene
Bristol-Myers Squibb has wrapped up its $74 billion acquisition of Celgene having got regulatory approval from all government…
Amgen to take 20.5% stake in Chinese biotech company BeiGene for $2.7bn
US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company…
Celgene bags Otezla FDA approval for oral ulcers in Behcet’s Disease
Otezla FDA approval : US biotech company Celgene has bagged approval from the US Food and Drug Administration…